AstraZeneca’s Head Of R&D Asia Patrick Keohane On Balancing East And West: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca's Head of R&D in Asia Patrick Keohane sat down recently with PharmAsia News' Australia bureau to talk about AstraZeneca's footprint in Asia and how the company's thinking is changing as a result of looking toward Asia.
You may also be interested in...
Despite Global Financial Crisis, China Pharma Market Expected To Grow At 20% Over Next Several Years
SHANGHAI - Despite the financial downturn, IMS China recently reported a 26 percent increase in growth for China's pharmaceutical market in 2008, bringing the total size of the market to approximately $25 billion. The growth rate is expected to hold steady at around 20 percent for the next several years, according to IMS Health analysts
Despite Global Financial Crisis, China Pharma Market Expected To Grow At 20% Over Next Several Years
SHANGHAI - Despite the financial downturn, IMS China recently reported a 26 percent increase in growth for China's pharmaceutical market in 2008, bringing the total size of the market to approximately $25 billion. The growth rate is expected to hold steady at around 20 percent for the next several years, according to IMS Health analysts
AstraZeneca Extends RSV Deal With Aussie Biotech Biota
PERTH, Australia - Melbourne-based Biota's 2005 antiviral collaboration and license agreement with MedImmune has been picked up by AstraZeneca and expanded to include a number of Asian territories, Biota announced Aug. 25